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Perspective
I
t is almost ten years since a clarion 
call was sounded to malaria 
researchers, funding agencies, 
governments, and international 
organisations to help avert “a 
malaria disaster” [1]. At that time, 
infrastructure in malaria control 
programmes across Africa was 
deteriorating. This deterioration was 
exacerbated by an alarmingly high 
prevalence of parasites resistant to the 
two affordable treatments being used 
across the continent: chloroquine and 
sulphadoxine-pyrimethamine. The 
plea was to speed up the introduction 
of combination therapies in which one 
of the component drugs was from a 
highly effective antimalarial class, the 
artemisinins, derived from the Chinese 
herbal remedy qinghaosu. Subsequent 
investment in research and clinical 
trials, and new drug procurement 
arrangements through the Global 
Fund to Fight AIDS, Tuberculosis 
and Malaria, have achieved much to 
be proud of. Many African countries 
have now implemented new malaria 
treatment policies centred around 
artemisinin combination therapy 
(ACT) as the front-line treatment for 
malaria.
Testing New Combinations Against 
Current Regimens
There is now an urgent need to bring 
new combination therapies into the 
malaria drug development pipeline, to 
provide endemic country governments 
with alternative regimens suited to 
malaria transmission in their setting, 
and to minimise the global impact 
of resistance to ACTs, should it arise. 
However, in order to be granted 
licensure, such new combinations 
must be tested against current ACT-
based regimens of high efficacy. 
Therefore the previously established 
phase III clinical trial designs, which 
test for superiority of the investigational 
product against a failing drug such 
as chloroquine or sulphadoxine-
pyrimethamine, can no longer apply. 
There are now important questions 
about the design and standardisation 
of such pre-licensure phase III 
antimalarial treatment trials. 
In a new Policy Forum on this topic, 
Steffen Borrmann and colleagues make 
important recommendations for such 
trials [2]. In particular, they advocate 
the use of a non-inferiority study design 
when deciding if a new regimen has 
an acceptable level of performance. In 
such a design, a new therapy is deemed 
acceptable for further investigation 
or licensure if it performs “at least 
as well as” a current therapy of good 
efficacy. The precise meaning of this 
phrase must be widely agreed before 
this approach can be adopted, and 
before future standardisation of such 
studies can be established. Borrmann 
and colleagues throw this debate 
open, but themselves advocate a “delta 
margin” (see Glossary) of 5%, with 
a fixed benchmark of at least 90% 
cure rate. Thus the efficacy of any 
new combination would be required 
to reach 95% of the efficacy of the 
established regimen, and cure at least 
90% of treated patients in a phase 
III study: violation of either criterion 
would mean the new therapy was not 
deemed of adequate efficacy. 
The Question of Efficacy Endpoints
However, we encounter dangerous 
waters when the question of efficacy 
endpoints arises—what are the 
appropriate measures of antimalarial 
efficacy when testing for non-inferiority 
with an established regimen in phase 
III studies? A feature of falciparum 
malaria efficacy studies over the last 
decade has been the use of so-called 
“PCR correction” (see Glossary) to 
distinguish between treatment failure 
caused by recrudescent parasites 
(i.e., those that are identical to 
pre-treatment parasites by genetic 
fingerprinting) and treatment failure 
caused by genetically distinct parasites 
that have emerged from the liver after 
treatment. Borrmann and colleagues 
skilfully navigate these waters, and 
finally recommend that the efficacy 
endpoint for phase III trials should be 
the absence of recrudescent parasites 
over 28 days of follow-up, verified by 
PCR correction [2].
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Linked Policy Forum 
This Perspective discusses the 
following new article published in PLoS 
Medicine:
Borrmann S, Peto T, Snow RW, 
Gutteridge W, White NJ (2008) Revisiting 
the design of phase III clinical trials of 
antimalarial drugs for uncomplicated 
Plasmodium falciparum malaria. PLoS 
Med 5(11): e227. doi:10.1371/journal.
pmed.0050227
Steffen Borrmann and colleagues 
discuss appropriate endpoints and their 
measurement during phase III trials of 
new antimalarial drugs.
The Perspective section is for experts to discuss the 
clinical practice or public health implications of a 
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An alternative view is that 
uncorrected estimates of antimalarial 
efficacy, combining therapeutic and 
prophylactic effects in a single measure, 
should be given primacy. The main 
justification for this unfashionable 
opinion is 2-fold. Firstly, there is no 
evidence of a clinically meaningful 
difference between recrudescent 
and newly emergent infections [3]. 
Secondly, PCR-corrected estimates of 
efficacy cannot be directly compared 
across studies. This is because the gap 
between corrected and uncorrected 
estimates will differ between trial 
sites as transmission intensity, levels 
of acquired immunity, prevalence 
of parasite resistance to ACT 
partner drugs (e.g., amodiaquine, 
lumefantrine), and the genetic 
complexity of the parasite population 
vary. These factors will influence 
the “PCR-corrected” estimate of 
efficacy, but only one (prevalence of 
resistance) is truly a component of 
“drug efficacy”. Thus PCR-corrected 
estimates of efficacy for a particular 
regimen in different sites should only 
be compared by normalising against 
a well-characterised comparator drug 
tested in both sites, using harmonised 
protocols, and this comparison should 
be on a population level, and not by 
re-classification of individual treatment 
failures [4]. 
Alternative Ways To Monitor Drug 
Performance
There are other ways of monitoring 
the performance of antimalarial drugs 
not considered by Borrmann and 
colleagues. Transmission endpoints, 
such as gametocyte carriage or the 
infectivity of treated individuals to 
Anopheles mosquitoes, provide early 
signals of developing P. falciparum 
resistance to antimalarial drugs, and 
could be more widely applied to 
comparative efficacy studies [5,6]. 
Efficacious drugs may also differ in 
the speed with which pre-treatment 
parasite densities are reduced, and 
a recent trial has used the parasite 
clearance time, monitored by repeat 
peripheral blood sampling over days 
1 to 3 post-treatment, to distinguish 
between regimens with good 14-day 
efficacy [7]. This approach, simplified 
to reduce the number of samples 
required, should also be used to 
monitor ACT efficacy for signs of 
increasing parasite clearance time as 
these valuable regimens are deployed 
across the globe.  
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Glossary
Delta margin: In the context of non-
inferiority clinical trials, the delta margin 
sets the efficacy benchmark below which 
the test drug fails to be “non-inferior” to 
the comparator drug. This benchmark 
is simply the measured efficacy of the 
comparator drug minus the delta margin; 
for a comparator with measured efficacy 
of, say, 96%, and a delta margin of 5%, 
the test drug must reach a measured 
efficacy of 91.2%. 
PCR correction: Use of genetic 
fingerprinting techniques, usually 
based on the polymorphic antigen 
loci pfmsp1 and pfmsp2, to determine 
whether P. falciparum parasites recurring 
in a patient’s peripheral blood after 
antimalarial treatment are genetically 
identical to, or different from, the 
parasites present prior to treatment. If 
identical to pre-treatment parasites, the 
recurrent infection is considered to be a 
recrudescence; if different it is considered 
to be newly emergent from the liver 
and not a treatment failure, sensu stricto. 
There is disagreement in the literature 
as to the validity of this approach for 
correcting estimates of drug efficacy. 